Incorporation of pseudocapsule presence into a modified Clear Cell Likelihood Score (m-ccLS) was associated with a greater than 11 percent higher AUC in differentiating benign and malignant renal masses on mpMRI, according to a new study.
|Articles|August 18, 1999
Nycomed submits ultrasound contrast NDA
Contrast agent developer Nycomed Amersham hopes soon to join the ultrasound contrast race. The Buckingham, U.K.-based firm has submitted a new drug application (NDA) to the Food and Drug Administration for Sonazoid, an ultrasound contrast agent formerly
Advertisement
Contrast agent developer Nycomed Amersham hopes soon to join the ultrasound contrast race. The Buckingham, U.K.-based firm has submitted a new drug application (NDA) to the Food and Drug Administration for Sonazoid, an ultrasound contrast agent formerly called NC100100. In support of its application, Nycomed has submitted clinical data demonstrating echocardiographic improvement in endocardial border delineation and left ventricular opacification when Sonazoid is used. Nycomed performed clinical trials for the agent on approximately 1300 patients in Europe and the U.S.
Nycomed has been defending patents covering the agents technology since 1997, when it became embroiled in a dispute with San Diego-based Molecular Biosystems and St. Louis-based Mallinckrodt (SCAN 4/29/98).
Developed for use in such cardiology and radiology applications as heart and liver imaging, Sonazoid is also being investigated for use in imaging myocardial perfusion. The companys Japanese partner in ultrasound contrast agent R&D, Daiichi Pharmaceutical, has completed phase I trials for liver and heart imaging applications for Sonazoid. Nycomed plans to submit an equivalent clearance document for the agent in Europe later this year.
Advertisement
Related to this article
For patients with hepatocellular carcinoma (HCC), perfusion beyond tumor margin on contrast-enhanced ultrasound that exceeds gray-scale ultrasound tumor measurement by 5 mm is associated with a 76 percent higher risk of worse recurrence-free survival, according to newly published research.
In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses the utility of prostatic artery embolization for treating benign prostatic hyperplasia, key imaging considerations and pertinent technique pearls to help facilitate optimal outcomes.
The AI-powered SwiftSight Body Composition software reportedly provides automated quantification of muscle and adipose tissue after a brief MRI scan.
In the second of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss how to handle disagreements with adjunctive AI in breast imaging, whether to include AI assessments in PACS, and whether patients should pay for the use of adjunctive AI.
Has the barrage of passwords, PINs and authenticator apps gone around the bend to a point where it hampers efficiency and productivity?
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Body Composition Analysis
2
Study Shows Impact of Key mpMRI Features for Enhancing Assessment of Renal Masses
3
Tumor Margin Marker on Contrast-Enhanced Ultrasound May Predict Worse Outcomes in Patients with HCC
4
Interventional Radiology in Focus: A Closer Look at Prostatic Artery Embolization for Benign Prostatic Hyperplasia
5